
Loading, please wait...

Loading, please wait...






For years, radioactive iodine (RAI) was standard for intermediate-risk papillary thyroid cancer. New research and the ATA 2025 guidelines now support a more selective approach, allowing many patients to avoid RAI based on postoperative markers and imaging without increasing recurrence risk.



